BR9915572A - Processo de tratamento de doença de célula falciforme e talassemia - Google Patents

Processo de tratamento de doença de célula falciforme e talassemia

Info

Publication number
BR9915572A
BR9915572A BR9915572-9A BR9915572A BR9915572A BR 9915572 A BR9915572 A BR 9915572A BR 9915572 A BR9915572 A BR 9915572A BR 9915572 A BR9915572 A BR 9915572A
Authority
BR
Brazil
Prior art keywords
thalassemia
treatment
sickle cell
cell disease
provides
Prior art date
Application number
BR9915572-9A
Other languages
English (en)
Inventor
Suzanne Lee Um
Sau-Chi Betty Yan
Barbara Gail Utterback
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of BR9915572A publication Critical patent/BR9915572A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4866—Protein C (3.4.21.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Patente de Invenção: <B>"PROCESSO DE TRATAMENTO DE DOENçA DE CéLULA FALCIFORME E TALASSEMIA"<D>. A presente invenção provê um processo de tratamento de doença de célula falciforme (SCD) ou talassemia com proteína C. A invenção reivindicada provê uma terapia necessária para distúrbios debilitantes e potencialmente sérios, enquanto evitando complicações tais como tendência a sangramento, toxidez e efeitos colaterais genéricos de agentes anticoagulantes correntemente disponíveis.
BR9915572-9A 1998-11-23 1999-11-16 Processo de tratamento de doença de célula falciforme e talassemia BR9915572A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10947498P 1998-11-23 1998-11-23
PCT/US1999/026958 WO2000030676A1 (en) 1998-11-23 1999-11-16 Method of treating sickle cell disease and thalassemia

Publications (1)

Publication Number Publication Date
BR9915572A true BR9915572A (pt) 2001-08-14

Family

ID=22327841

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9915572-9A BR9915572A (pt) 1998-11-23 1999-11-16 Processo de tratamento de doença de célula falciforme e talassemia

Country Status (14)

Country Link
US (1) US6372213B2 (pt)
EP (1) EP1133314B1 (pt)
JP (1) JP2002530352A (pt)
CN (1) CN1326357A (pt)
AT (1) ATE232739T1 (pt)
AU (1) AU1723200A (pt)
BR (1) BR9915572A (pt)
CA (1) CA2351591A1 (pt)
DE (1) DE69905489T2 (pt)
DK (1) DK1133314T3 (pt)
ES (1) ES2192874T3 (pt)
IL (1) IL142247A0 (pt)
WO (1) WO2000030676A1 (pt)
ZA (1) ZA200102727B (pt)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001290553A1 (en) * 2000-09-18 2002-04-02 Eli Lilly And Company Method for using activated protein c for the treatment of coagulation-associated disorders
US20060246161A1 (en) * 2003-02-21 2006-11-02 Hongtao Xing Method of making medicament for treating anemia
EP2815749A1 (en) 2013-06-20 2014-12-24 IP Gesellschaft für Management mbH Solid form of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione having specified X-ray diffraction pattern
WO2018013693A1 (en) 2016-07-13 2018-01-18 Celgene Corporation Solid dispersions and cocrystals comprising 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione compositions and methods of use thereof
WO2018013689A1 (en) 2016-07-13 2018-01-18 Celgene Corporation Solid dispersions and solid forms comprising 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione, method of preparation and use thereof
CN106399478B (zh) 2016-08-31 2024-09-03 桂林优利特医疗电子有限公司 一种荧光探针PCR法快速检测α/β-地中海贫血的试剂盒

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4775624A (en) 1985-02-08 1988-10-04 Eli Lilly And Company Vectors and compounds for expression of human protein C
US5516650A (en) 1985-06-27 1996-05-14 Zymogenetics, Inc. Production of activated protein C
US5550036A (en) 1986-04-09 1996-08-27 Eli Lilly And Company Method for co-amplification of human protein C genes in human cells
US5084274A (en) 1987-11-17 1992-01-28 Scripps Clinic And Research Foundation Inhibition of arterial thrombotic occlusion or thromboembolism
US4992373A (en) 1987-12-04 1991-02-12 Eli Lilly And Company Vectors and compounds for direct expression of activated human protein C
GB8819607D0 (en) 1988-08-17 1988-09-21 Wellcome Found Novel combination
US4981952A (en) 1988-10-04 1991-01-01 Eli Lilly And Company Method for the purification of vitamin K-dependent proteins
IL97312A (en) 1990-02-23 1999-01-26 Lilly Co Eli A method of generating a polypeptide in an eukaryotic vector AND recombinant surrogate cell containing an enhanced transcriptional control unit based on the primary late adenovirus coefficient
AT402262B (de) 1991-06-20 1997-03-25 Immuno Ag Arzneimittel enthaltend aktiviertes protein c
MY110664A (en) 1992-05-21 1999-01-30 Lilly Co Eli Protein c derivatives
WO1997020043A1 (en) 1995-11-30 1997-06-05 Zymogenetics, Inc. Protein c production in transgenic animals
BR9809304B1 (pt) * 1997-04-28 2011-02-08 formulação liofilizada estável, processo para preparação da mesma, bem como forma de dosagem unitária.
HUP0001237A3 (en) * 1997-10-20 2002-01-28 Lilly Co Eli Methods for treating vascular disorders

Also Published As

Publication number Publication date
EP1133314A1 (en) 2001-09-19
WO2000030676A1 (en) 2000-06-02
ZA200102727B (en) 2002-09-25
DE69905489T2 (de) 2003-09-11
AU1723200A (en) 2000-06-13
ATE232739T1 (de) 2003-03-15
US20020012662A1 (en) 2002-01-31
EP1133314B1 (en) 2003-02-19
ES2192874T3 (es) 2003-10-16
CA2351591A1 (en) 2000-06-02
DE69905489D1 (de) 2003-03-27
IL142247A0 (en) 2002-03-10
US6372213B2 (en) 2002-04-16
JP2002530352A (ja) 2002-09-17
DK1133314T3 (da) 2003-04-14
CN1326357A (zh) 2001-12-12

Similar Documents

Publication Publication Date Title
BR9610838A (pt) Processo para tratar um indivìduo tendo uma condição patológica envolvendo neovascularização.
BR9713186A (pt) Inibidores de metaloprotease 1,3-diheterocìclicos
BR9812837A (pt) Processo para fazer um composto, e, composto
BR9909844A (pt) Processo para sintetizar um composto, e, composto.
ATE134373T1 (de) Dopamin-agonisten
BR9811099A (pt) Inibidores de urocinase
BR0316723A (pt) Derivados de anilinopirazol úteis para o tratamento de diabetes
ES2026314A6 (es) Procedimiento para obtener una composicion profilactica antimicrobiana oftalmica neonatal.
BR9915460A (pt) Método de tratamento de febre hemorrágica virótica
BR9915572A (pt) Processo de tratamento de doença de célula falciforme e talassemia
BR9808923A (pt) Composto, e, processo para fazer o mesmo
CA2296560A1 (en) Amino acid derivatives useful to treat stroke
AP2000001937A0 (en) Method for identifying chemical active agents and active agents for inhibiting the 1-desoxy-d-xylulose-5-phosphate biosynthetic pathway.
WO1999058098A8 (en) HUMAN ANTITHROMBIN IIIs AND METHODS RELATED THERETO
DE69930419D1 (de) Verwendung von menschliche protein c zur herstellung eines arzneimittels zur behandlung von heparininduzierter thrombozytopenie
PT703232E (pt) Derivados do 2,3-di-hidro-1h-isoindole processo para a sua preparacao e o seu uso como inibidores da reassimilacao da serotonina
ATE357914T1 (de) Verwendung von 4-aminopyridin zur behandlung von peripheren neuropathien
DK0378146T3 (da) Polyamin-derivater som antineoplastiske midler
ATE242763T1 (de) Methoximinophenylessigsäureamide
WO1998023574A8 (en) Asiatic acid derivatives and medicines for treating wounds, which contains the same
WO2001034553A3 (en) 2,2-difluoro 15-hydroxyeicosatetraenoic acid analogs and methods of use
ATE258550T1 (de) Oxirancarbonsäuren für die behandlung von diabetes
AU5857899A (en) Use of tgf-beta inhibitors for treating cerebral disorders
UA42749C2 (uk) N,n-діетил-8,8-дипропіл-2-азаспіро[4,5]декан-2-пропанамін дималеат, фармацевтична композиція, спосіб лікування
BR9807920A (pt) Processos para tratamento de uma demência em um sujeito e para prevenção de uma demência

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]